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1. Introduction  
Many individual therapeutic strategies involving oral delivery of diabetes autoantigens such 
as insulin and GAD have been shown to provide partial short term suppression of organ 
specific type 1 diabetes autoimmunity (Weiner et al. 1991; Zhang et al. 1991; Nakayama et al. 
2005). However, few individual therapies have been able to demonstrate effective, safe and 
persistent protection against type 1 diabetes onset or progression (Hutchings and Cooke 
1998). More recently, combinatorial therapeutic strategies that incorporate 
immunostimulatory molecules such as the cholera toxin B subunit (CTB), linked to a 
diabetes autoantigen (eg. insulin or GAD), were shown to substantially enhance immune 
suppression of juvenile (Type 1) diabetes autoimmunity to provide more effective, safe and 
sustainable disease prevention (Arakawa et al. 1998; Denes et al. 2006). Combinatorial 
vaccines involving oral delivery of the cholera toxin B subunit (CTB) linked to pancreatic 
autoantigens such as proinsulin and GAD delivered together were shown to provide 
additive enhancement of autoantigen mediated suppression of diabetes insulitis and 
hyperglycemia in contrast to inoculation of prediabetic mice with CTB::GAD or 
CTB::proinsulin alone (Arakawa, Chong, and Langridge 1998). Most recently, combinatorial 
DNA vaccination experiments including genes encoding CTB::GAD together with the 
immunosuppressive cytokine IL-10 were shown to completely suppress type 1 diabetes 
onset in non-obese prediabetic (NOD) mice (Denes et al. 2010).  Thus, it is now clear that 
combinatorial vaccination strategies have the ability to completely prevent diabetes onset in 
genetically susceptible mammals.  
However, to harness and transfer this promising combinatorial vaccination strategy for 
effective and safe clinical therapy in type 1 diabetes patients, cellular and molecular 
mechanisms underlying multi-component vaccine stimulation of immunological tolerance 
must be defined.  Initial steps required to attain this goal, will involve identification of 
mechanisms responsible for vaccine interactions with cells of the innate immune system i.e., 
dendritic cells (DCs), involved in the initial processing vaccine autoantigens.  
In order to understand how multi-component vaccines may function to prevent the 
development of chronic islet inflammation (insulitis) progressing to high blood sugar 
(hyperglycemia), it will be important to understand the nature of immune responses 
underlying type 1 diabetes disease onset. To accomplish this goal, hypotheses must be tested 
that suggest how adjuvant-autoantigen fusion proteins may enhance immunotolerance e.g. 
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through initial activation of sensor cells of the innate immune system predominantly 
immature dendritic cells (iDC). Of importance will be to determine how DCs process 
adjuvant-autoantigen fusion proteins, and how these processing reactions result in the 
initiation of immuno-reactive or immuno-suppressive T cell populations responsible for 
inhibiting the development of autoreactive effector T cell responses? Throughout the 
development of this review, we will examine the role of protein adjuvants such as CTB in 
combination with autoantgens and anti-inflammatory cytokines that can act in concert to 
stimulate proliferation and activation of regulatory T cell subsets potentially key players in 
the inhibition of DC maturation and stimulation of T cell morphogenesis into autoreactive T 
cells. To rescue the large numbers of existing diabetes patients in which diabetes has 
progressed to a hyperglycemic state, it will be important to understand mechanisms 
responsible for diabetes development and how combinatorial vaccines may interact with 
cells of the immune system to suppress diabetes progression. An improved understanding 
of these mechanisms will establish a basis for development of safer, more effective and 
durable vaccine strategies for prevention of diabetes onset and for improvement of 
combinatorial therapeutic strategies for restoration of immunological homeostasis and 
ultimately restoration of euglycemia in type 1 diabetes patients.  
2. Type 1 diabetes results from genetic predisposition and a breakdown in 
the mechanisms responsible for immunological tolerance 
 In juvenile diabetes mellitus, (type 1 diabetes), insulin-producing beta cells in the pancreatic 
Islets of Langerhans are attacked and destroyed by aberrant immune responses to insulin 
and progressively to other islet beta cell products.  Diabetic patients that have progressed to 
hyperglycemia must regularly inject insulin multiple times a day, or risk diabetic shock, 
coma and death.  Regulation of immunological homeostasis, among the approximate 1014 
commensal microorganisms living on the 1013 cells of the human body’s mucosae requires a 
delicate balance of activation and suppression of immunity, (Lodinova-Zadnikova et al. 
2004). The first step in disruption of homeostasis leading to islet-cell mortality is initiated by 
events that trigger maturation of antigen-presenting cells (APCs), largely dendritic cells 
(DC), responsible for inducing the morphogenesis of autoreactive CD8+, CD4+ T cells and B 
cells, which results in the production of anti-beta cell antibodies (Atkinson et al. 1994; Han et 
al. 2005; Tisch and McDevitt 1996). The continuous loss of islet -cell function results in a 
progressive  deficiency of insulin production leading to a gradual elevation of blood sugar 
levels (hyperglycemia), that triggers an increase in cellular oxidative stress leading to 
chronic inflammation and an associated risk for secondary neural and circulatory 
pathological complications that include amputation, blindness, kidney failure, heart attack 
and stroke (Libby et al. 2005; Shen and Bornfeldt 2007). Diabetes hyperglycemia represents 
the end stage of an immunological process that develops over months in mice to years in 
humans (Vendrame, Zappaterreno, and Dotta 2004). While most type 1 diabetes (T1D) cases 
develop in pre-adolescence, late onset diabetes (LADA), may appear generally from 40–60 
yr of age and is often confused with type 2 diabetes. The progression of diabetes symptoms 
may be responsible for 10–15% of diabetes related heart disease mortality especially in low 
income socio-economic groups which are at greatest risk for diabetes related health 
disparities in the U.S (Kobayashi et al. 2006; Maioli, Puddu, and Pes 2006). Diagnosis and 
treatment of hyperglycemia is poor, as islet -cell destruction is completely asymptomatic 
until more than half of the approximately 1x106 pancreatic islets have been destroyed or 
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inactivated (Tang et al. 2006). Approximately 3 million Americans, or about 15-20% of 
citizens currently afflicted with all forms of diabetes, suffer from type 1 diabetes and > 
13,000 children are diagnosed with type 1 diabetes in the U.S. annually – (about 35 children 
/ day), (International 2005). Alarmingly, type 1 diabetes in pre-adolescent children is 
increasing at about 0.3-0.5% annually, (Gale 2002; International 2005). Familial inheritance 
studies show that genetic predisposition factors (genotype DRB1*0301/04, 
DQB1*0201/0302), play a significant role in T1D development (Rewers et al. 1996). At least 
15 genetic loci have been linked to T1D in the non-obese diabetic (NOD) mouse, a relevant 
mammalian T1D model (Makino et al. 1980). In humans, genetic risk factors were identified 
in the leukocyte antigen (HLA) complex on chromosome 6, CTLA-4 gene polymorphisms on 
chromosome 2, and in the insulin gene variable number tandem repeat region on 
chromosome 11 (Onengut-Gumuscu and Concannon 2002). Since Type 1 diabetes ranges 
from 23 - 53% among monozygotic twins, genetic risk factors are insufficient to account for 
disease occurrence (Tatersall  R. B. 1972). 
Environmental factors, including virus infection and dietary components are considered to 
modify diabetes susceptibility (Jun and Yoon 2001; Akerblom HK 2002). Cytotoxic CD8+ T 
cells were shown to be involved in diabetes initiation and progression(Walter and 
Santamaria 2005). Further, recruitment of naïve diabetogenic -cell-reactive CTLs to the 
pancreatic islets were shown to require -cell-reactive CD4+ Th1 cells(Delovitch and Singh 
1997). Following CD4+ Th cell infiltration of pancreatic islets in NOD mice, autoreactive Th1 
lymphocytes were shown to secrete inflammatory cytokines IFN- and IL-2 that stimulate 
macrophage and CTL secretion of oxidative compounds and inflammatory cytokines that 
induce chronic pancreatic inflammation (insulitis), ultimately responsible for apoptosis of 
islet insulin-producing -cells(Romagnani 1998). Diabetes onset is not always marked by 
circulating auto-Ab to -cell autoantigens and a variety of immune cells including B cells, 
dendritic cells, macrophages and natural killer (NK) cells have been shown to be involved in 
diabetes pathogenesis(Yoon, Jun, and Santamaria 1998; Dai, Carayanniotis, and Sercarz 
2005; Tian et al. 2006; Silveira and Grey 2006; Cardell 2006). A recently identified rat diabetes 
model was shown to be quantitatively up-regulated from 2.0 -100% diabetes by antibody 
depletion of regulatory T cells suggesting a significant role for regulatory T cells in diabetes 
suppression(Mordes et al. 2005). Thus, dendritic cell, autoreactive T cell, T regulatory cell 
and B cell pathways may all interact to establish or break immunological 
homeostasis(Mostarica-Stojkovic 2005). 
2.1 Diabetes autoantigen therapy can restore immunological tolerance 
While, deletion of autoreactive T cells is generally achieved in the thymus (central 
tolerance), a few autoreactive T lymphocytes escape deletion and appear in the 
periphery(Song et al. 2004). Interestingly, autoreactive T cell clones specific for self-proteins 
were shown to arise spontaneously from normal peripheral blood mononuclear cells in 
healthy people (Wucherpfennig et al. 1994). Thus, autoimmunity may have the opportunity 
to exist to some degree in everyone. Insulin was shown to be an early major diabetes 
autoantigen(Palmer et al. 1983; Jaeckel, Lipes, and von Boehmer 2004; Jaeckel et al. 2003; 
Kent et al. 2005). The insulin leader, A, B and C protein chains all were shown to contain 
CD4+ and CD8+ immunodominant T cell epitopes (Di Lorenzo, Peakman, and Roep 2007). 
Progressive islet -cell destruction was shown to lead to the appearance of additional -cell 
autoantigens (Ag spreading), a factor that exacerbates -cell destruction(Baekkeskov et al. 
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1990). Immunotherapy with major -cell antigens such as insulin, glutamate decarboxylase 
(GAD), or heat shock protein (hsp60), was shown to delay or even prevent the onset of type 
1 diabetes, providing a potentially useful therapeutic approach to treatment of T cell-
mediated autoimmunity(Elliott et al. 1994; Tisch and McDevitt 1996). Oral inoculation with 
small amounts of islet autoantigens was shown to induce self-tolerance through IL-4 and 
Stat 6 activation of CD4+ Th2 and Th3 regulatory T cells that down-modulate autoreactive 
effector T cell inflammation at close proximity e.g., “bystander suppression”, (Hommann et 
al. 2001; Weiner 2001). Protection against T1D was shown to be associated with Th3 
regulatory lymphocyte secretion of TGF- in prediabetic NOD mice gavaged with insulin, 
(Zhang et al. 1991). Further, oral auto-Ag inoculation generated partial diabetes suppression 
in patients (Millington, Mowat, and Garside 2004; Chaillous et al. 2000). In several related 
Th1 cell mediated autoimmune diseases, collagen-induced arthritis (Thompson and Staines 
1986) and encephalomyelitis (Higgins and Weiner 1988) disease suppression was observed 
after prolonged feeding of small amounts of specific auto-Ags. The induction of multiple 
sclerosis in animals was not only halted but reversed by feeding small amounts of myelin 
basic protein suggesting that this type of oral auto-Ag therapy can suppress and even aid in 
recovery from autoimmunity (Bitar and Whitacre 1988). 
2.2 Cholera toxin B subunit (CTB), enhances autoantigen mediated immunotolerance 
Immunotherapy with adjuvants such as Complete Freund’s Adjuvant (CFA) co-injected 
intradermally with insulin, or inoculation with CTB-insulin B chain polypeptide fusion 
proteins significantly suppressed diabetes early onset demonstrating the usefulness of 
immunostimulatory molecules in diabetes suppression (Hutchings and Cooke 1998).  
Additional studies in BB rats suggest that CFA may mediate diabetes suppression through 
induction of regulatory T cells (Qin et al. 1993). Thus, a number of biological mechanisms 
may contribute to suppression of autoimmunity.  Cholera toxin (CTX), from Vibrio cholerae 
contains a toxic ADP-ribosyltransferase A subunit (CTA1), linked by a small helical (A2) 
peptide to a pentamer of non-toxic carrier B subunits (CTB), (Eriksson and Holmgren 2002). 
CTX induces DC maturation and migration to the Peyer’s patches while the CTB subunit 
was shown to inhibit DC maturation and to bind GM1-ganglioside, a receptor found on 
most epidermal cells, thereby providing an efficient transmucosal carrier for autoantigen 
induction of peripheral tolerance (Shreedhar, Kelsall, and Neutra 2003; Lycke 2004; Sun, 
Holmgren, and Czerkinsky 1994). Oral delivery of CTB was shown to directly stimulate DC 
induction of T cell IL-4 secretion and to exert a variety of distinct anti-inflammatory effects 
resulting in immunological suppression (Holmgren et al. 1994; Li and Fox 1996; Holmgren 
and Czerkinsky 2005). Oral delivery of CTB conjugated to specific autoantigens was shown 
to protect mice against several Th1 cell mediated autoimmune diseases including 
autoimmune encephalomyelitis (Sun et al. 1996; Sun et al. 2000), autoimmune chondritis 
(Kim et al. 2001) and uveitis (Phipps et al. 2003). Further, CTB-insulin conjugates were 
shown to suppress diabetes in NOD mice (Bergerot et al. 1997; Arakawa, Chong, and 
Langridge 1998), a result associated with reduced IFN- production and Tr1 regulatory T 
cell migration into pancreatic islets (Aspord et al. 2002; Roncarolo et al. 2001). Further, 
linkage of CTB to insulin generated up to a 10,000-fold reduction in autoantigen required for 
immuno-tolerization (Bergerot et al. 1997; Arakawa et al. 1998; George-Chandy et al. 2001). 
Thus, current evidence suggests that mechanisms responsible for CTB modulated immune 
suppression may include inhibition of DC maturation by suppressing the expression of 
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surface co-stimulatory molecules resulting in the increased secretion of IL-10 and a 
concurrent suppression of IL-12, inhibition of autoreactive T cell development and/or 
stimulation of Th2 and regulatory T cell proliferation and activation (Marinaro et al. 1995; 
Lavelle et al. 2003; Odumosu et al. 2010). 
2.3 Dendritic cells can initiate immunological tolerance 
Dendritic cells may play a primary role in antigen priming of naïve T helper cells (Th0) and 
modulation of their development into autoreactive Th1 or immunosuppressive Th2 
lymphocytes important for maintenance of immunological homeostasis (Pulendran et al. 
1999; Pulendran et al. 2001; Itano et al. 2003).  
Immuno-cytochemical analyses showed that oral inoculation of autoantigens results in their 
uptake from M cells in the intestinal mucosa into peripheral (lamina propria) DCs via 
several routes that may influence the nature of the immune response (Yoon and Jun 2005). 
 
 
Fig. 1. Adjuvant-autoantigen fusion protein suppression of autoimmunity. Immature 
dendritic cells (iDC) take up CTB:GAD/Insulin autoantigen fusion proteins through the 
intestinal epithelium. Low levels of oral delivered auto-Ags stimulate DC secretion of anti-
inflammatory cytokines IL-10 and IL-4 which guide cognate naïve Th0 lymphocyte 
development of into immunosuppressive Th2 and iTreg lymphocyte phenotypes (Iwasaki 
and Kelsall 2000; Afzali et al. 2007).  
Autoantigens may be taken up and processed by immature, partially activated semi-mature 
or mature DC subsets (Lutz and Schuler 2002). These DCs may remain in the periphery or 
migrate to lymph nodes, where they present antigen peptides on MHCII receptors, 
synthesize co-stimulatory molecules and in the absence of additional cytokine production, 
may induce the morphogenesis of Ag-specific IL-10 producing CD4+CD25+ T regulatory 
(Tr1) cells (Enk 2005) Figure 1. Co-stimulation appears to be less or absent for tolerogenic 
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responses, thus, interactions between autoantigens, DCs and T cells in the gut associated 
lymphoid tissues may result in tolerogenic outcomes following autoAg presentation (Lycke 
2004).  Peyer’s patches DCs that synthesize IL-10 were shown to down-regulate Th1 cell 
mediated autoimmunity (Steinbrink et al. 1997). Immature or peripheral DCs (iDCs), that 
had low expression of co-stimulatory molecules, secreted cytokine IL-10, remained in the 
periphery and were shown to induce Th2 lymphocyte mediated immunological tolerance 
(Rissoan et al. 1999; Liu et al. 2001; Li et al. 2006). Further studies showed that a major 
function of peripheral iDCs was maintenance of self-tolerance (Wilson, El-Sukkari, and 
Villadangos 2004; Steinman and Pope 2002). In alternative, experiments, adding IL-12 to 
iDCs induced Th1 cell morphogenesis and accelerated type 1 diabetes in NOD mice 
(Trembleau et al. 1995). In response to microbial antigens, DCs may secrete inflammatory 
cytokines IL-6 and IL-23 that stimulate naïve Th0 cell development into IL-17 inflammatory 
cytokine secreting Th17 effector T cells (Figure 1). Th17 cells have been implicated in the 
induction of organ-specific autoimmune arthritis, multiple sclerosis, psoriasis, and 
inflammatory bowel disease as well as type 1 diabetes (Cua et al. 2003; Langrish et al. 2005; 
Duerr et al. 2006; Murphy et al. 2003; Nakae et al. 2003; Zheng et al. 2007; Mensah-Brown, 
Shahin, Al-Shamisi et al. 2006; Mensah-Brown, Shahin, Al-Shamsi et al. 2006). Together, the 
experimental evidence suggests development of type 1 diabetes may be under DC control 
(Shinomiya et al. 1999).  However, there is some debate about the role of Th17 cells in 
diabetogenesis suggesting that Th17 cells are not important in the disease process but rather 
are plastic cell that become become Th1(Bending et al. 2009). 
2.4 CTB enhances immune tolerance by upregulating DC tolerogenic toll-like 
receptors 
Dendritic cells, macrophages, and granulocytes derived from hematopoietic stem cells 
provide the first line of defense against infectious pathogens attacking mucosal surfaces. 
Thus, DCs (found in most abundance in the mucosae and skin), must recognize pathogen 
antigens, autoantigens and innocuous antigens in order to maintain immunological 
homeostasis. To accomplish this task, DCs bind small conserved pathogen antigen segments; 
pathogen associated molecular patterns (PAMPS), to their trans-membrane toll- 
like receptor (TLR) domains, (Takeda, Kaisho, and Akira 2003; Wen et al. 2004). Different 
PAMPS stimulate specific TLRs that activate one of several DC signal transduction 
pathways leading to synthesis of transcriptional regulators e.g., NFkB. These transcriptional 
activators switch on genes encoding specific cytokines, costimulatory molecules and 
chemokines that enable DCs to direct naïve cognate Th0 cell development into (1) 
immunoreactive Th1 lymphocytes, (2) immunosuppressive Th2 effector cell and (3) T 
regulatory cell subsets (Kaisho and Akira 2002). Autoreactive T cells involved in 
experimental autoimmune encephalomyelitis (EAE) and other chronic inflammatory 
autoimmune diseases are considered to follow TLR defined pathways of DC processing and 
auto-Ag presentation triggered by environment signals (Haverkos et al. 2003; Bach 2005).  
Recently, examination of TLR2 and TLR4 expression in monocytes from T1D patients 
showed that TLR2 and TLR4 surface expression and mRNAs were significantly increased in 
T1D monocytes in comparison with the controls (Devaraj et al. 2007). Further, downstream 
targets of TLRs, NFKb, MyD88, Trif and pIRAK, were also significantly upregulated. 
Antigen ligation to TLR2 is generally known to induce a Th2 immunosuppressive cytokine 
profile (Ferwerda et al. 2005). Whether CTB binds and activates TLR2 or TLR4 is presently 
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Fig. 2. Measurement of anti-inflammatory cytokine IL-10 and inflammatory cytokine IL-
12/23p40 subunit levels by Cytometric Bead Array flow cytometry, from cell supernatants 
removed from iDCs inoculated with CTB-insulin (CTB::INS) fusion protein, (Panel A) or 
CTB::GAD fusion protein (Panel B). For each treatment the concentration of IL-10 and IL-
12/23p40 subunit was normalized to standard IL-10 and IL-12/23p40 cytokine curve and 
given in pg/ml. The data represent the Mean and SE (*P<0.001) of repeated independent 
experiments in comparison with the control sample.  
unknown. However, the structurally similar E. coli AB enterotoxin B subunit (LTB) was 
shown to stimulate TLR2, resulting in regulatory T cell proliferation which ultimately lead 
to inhibition of iDC maturation, IL-10 secretion and induction of immunosuppressive Th2 
lymphocyte development (Hajishengallis et al. 2005; Sutmuller et al. 2006). Examination of 
CTB mediated suppression of DC maturation suggests that TLR2 may be selectively 
upregulated (Odumosu et al. 2010). The observed selectivity may be due to TLR2 dependent 
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hydrophobic interactions for ligand binding as previously observed for the E. coli 
enterotoxin B subunit LTBIIb (Seong and Matzinger 2004; Okusawa et al. 2004). 
Alternatively, multiple bacterial products including lipo-polysaccharide (LPS), were shown 
to undergo DC processing independently of TLR signaling, via stimulation of the pannexin -
1 hemi-channel protein–cryopyrin receptor pathway (Kanneganti et al. 2007) Thus, in 
addition to immunosuppressive TLR receptor binding, alternative signaling pathways could 
be involved in iDC processing of CTB-INS fusion protein potentially favoring CTB induced 
DC synthesis of IL-10 leading to induction of Th0 -> Th2 cell morphogenesis and 
suppression of autoreactive Th1 lymphocyte development ( Figure 2).  
2.5 Regulatory T cells inhibit dendritic cell maturation 
The suppression of autoreactive T cells is essential for establishment of peripheral 
tolerance and maintenance of immunological homeostasis, (Vigouroux et al. 2004; Stassen 
et al. 2004). Natural CD4+CD25+ regulatory T cells (nTregs) of thymus origin, have a high 
avidity for self-antigens and were shown to link central tolerance to induction of 
regulatory functions in the periphery (Sakaguchi et al. 1995; Sakaguchi and Sakaguchi 
2005; Sakaguchi 2005; Taams and Akbar 2005; Bresson et al. 2006). Natural Treg 
immunosuppressive functions are antigen independent and are largely under control of 
the forkhead box p3 transcription factor FOXP3 (Fontenot, Gavin and Rudensky 2003; 
Hori, Nomura and Sakaguchi 2003). While nTregs inhibit DC maturation in an antigen 
independent manner, they were also shown to be important for down-regulating Th1 cell 
mediated autoimmunity in thyroiditis, diabetes, encephalomyelitis, and oophoritis 
(Tarbell et al. 2004). Further, the glucocorticoid-induced tumor necrosis factor receptor 
(GITR), cytotoxic T-lymphocyte antigen 4 (CTLA-4), and LAG-3 surface markers were 
identified on antigen-activated nTregs (Nocentini and Riccardi 2005; Huang et al. 2004; 
Oderup et al. 2006). Further evidence supporting Treg suppression of autoimmunity, 
mutations in the mouse foxp3 gene resulted in development of systemic autoimmunity, 
characterized by inflammatory lymphocyte infiltration and destruction of tissues by 
autoreactive T-cells, leading to spontaneous development of a number of Th1 cell 
mediated autoimmune diseases including type 1 diabetes (Hori and Sakaguchi 2004; 
Ehrenstein et al. 2004; Lindley et al. 2005; Viglietta et al. 2004). 
Incubation of DCs with nTregs increased IL-10 secretion and reduced CD40, CD80/86 co-
stimulatory molecule expression reinforcing the hypothesis that nTregs modulate 
autoimmunity through suppression of DC immunostimulatory functions (Veldhoen et al. 
2006; Misra et al. 2004; Yang et al. 2006). Recent experiments clearly show that Tregs interact 
with antigen-bearing DCs to prevent naïve autoreactive CD4+CD25-- effector Th0 cell 
priming (Tang et al. 2006). Adoptive transfer experiments further confirmed nTreg-DC 
interaction was essential for autoreactive Th1 cell inhibition (Tarbell et al. 2004; Kelsen et al. 
2006). Regulation of DC processing of autoantigens, in the absence of sufficient nTregs, 
requires additional regulatory T cell induction from the CD4+ CD25-- T cell 
population(Bluestone and Abbas 2003; Filippi, Bresson, and von Herrath 2005) .  Two 
human CD4+CD25+ nTreg subsets were shown to convey immuno-suppressive capabilities 
to CD4+ CD25-- T cells. Natural Tregs expressing 4┚7 integrin induced IL-10 secreting Tr1-
like suppressor T cells, while nTregs expressing 4┚1 integrin induced TGF-┚ secreting Th3-
like suppressor T cells (Stassen et al. 2004). Secreted TGF-┚1 was shown to suppress DC 
activation during maturation (Rastellini et al. 1995; Yamaguchi et al. 1997; King et al. 1998). 
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Further, TGF-┚1 inhibited DC expression of chemokine receptor CCR7, responsible for DC 
migration to lymph nodes (MartIn-Fontecha et al. 2003). Secretion of IL-10 by Tr1 iTregs 
inhibited DC maturation by blocking IL-12 synthesis and skewing Th1/Th2 polarity toward 
Th2 cells in vivo by inhibiting both Th1 cell proliferation and monocyte secretion of IFN-┛, 
TNF- and IL-2 cytokines (De Smedt et al. 1997; Sela 2006). DCs were shown to expand and 
differentiate Foxp3+CD25+CD4+ Tregs from Foxp3–CD25–CD4+ thymocytes with 
specificity for self-antigens presented by thymic medullary DCs maturing in response to 
thymic stromal lymphopoietin (Watanabe et al. 2005). In vivo, repeated injection of 
preprocessed peptides (Apostolou and von Boehmer 2004) or the targeting of intact antigens 
to immature DCs (Kretschmer et al. 2005) convert antigen-specific Foxp3–CD25–CD4+ T 
cells to Foxp3+CD25+CD4+ Tregs bearing the same TCR. DCs also induce other regulatory 
populations, such as IL-10-producing Tr1 (Levings et al. 2005; Akbari, DeKruyff, and 
Umetsu 2001; Akbari et al. 2002; Stock et al. 2004) and IL-10-producing regulatory DCs (Kojo 
et al. 2005). Diabetes-susceptible NOD mice appear to generate normal numbers of Foxp3 T-
cells over their lifetimes (Tritt et al. 2008). However, Piccirillo and his colleagues at McGill 
University showed that T-cell functional potency declined with age, leaving potential 
autoimmune responses in the pancreas unchecked. These authors suggest that certain genetic 
predispositions, coupled with the possible contribution of external environmental factors or 
infections, could potentially alter regulatory T-cell function in susceptible individuals and 
trigger a full-scale diabetic autoimmune reaction in the pancreas (Tritt et al. 2008).  
 
 
2.6 Immunosuppressive properties of anti-inflammatory cytokine IL-10 
Human IL-10 is a homodimeric anti-inflammatory cytokine protein (molecular structure at 
left), with a subunit length of 160 amino acids and 73 percent amino acid homology with its 
murine orthologue(Yoon et al. 2006; Moore et al. 1990). Mouse knockout studies showed 
that IL-10 down-regulates autoimmunity in the intestinal tract and is active in suppression 
of Crohn’s disease (Minderhoud, Samsom, and Oldenburg 2007, 2007). In confirmation, the 
inability to clear persistent viral infections was shown to result from T-cell inactivation 
generated by APC up-regulation of anti-inflammatory IL-10 biosynthesis (Seyfert-Margolis 
et al. 2006). Thus, suppression of inflammatory responses mediated by DC up-regulation of 
IL-10 may play a significant role in virus-mediated suppression of type 1 diabetes in NOD 
mice and BB rats (Tracy and Drescher 2007; Schwimmbeck, Dyrberg, and Oldstone 1988). 
Alternative mechanisms that may play a role in cytokine enhancement of immune 
suppression include IL-10 blockage of NF-kappa B activity and regulation of the JAK-STAT 
signaling pathway (Donnelly, Dickensheets, and Finbloom 1999; Leceta et al. 2000). 
A regulatory role for autocrine IL-10 has been described for APCs such as monocytes, 
macrophages and dendritic cells (de Waal Malefyt et al. 1991; Sica et al. 2000). Autocrine 
Ribon 
diagram of 
Human IL-10 
www.intechopen.com
 
Type 1 Diabetes – Pathogenesis, Genetics and Immunotherapy 
 
462 
production of IL-10 by immature DCs, was shown to inhibit production and release of pro-
inflammatory cytokines (IL-12, TNF-┙, IL-6, LTB4, NO, PGE2), and to suppress Th1 
lymphocyte activity by down-regulation of costimulatory molecule expression on the APC 
surface (Harizi and Gualde 2006; Grutz 2005; Moore et al. 1993). Through inhibition of these 
endogenous pro-inflammatory mediators, IL-10 has demonstrated a central role in down-
regulating DC mediated inflammatory responses and maintenance of DCs in an immature 
state (Harizi and Gualde 2006).  
In paracrine fashion, IL-10 synthesized by DCs can regulate immune responses by altering 
the function of different adjacent cell types. In several studies IL-10 secreted by iDCs 
stimulated morphogenesis of cognate Th0 cell development into immunosuppressive Th2 
lymphocytes, or into suppressor CD4+ regulatory T cells (Stassen, Schmitt, and Jonuleit 
2004; Romagnani et al. 1998). In addition, IL-10 was shown to increase effector functions of 
CD8+ T cells (Groux et al. 1999). In addition, IL-10 may be crucial for controlling chronic 
inflammatory responses in vivo. Inhibition of LPS-induced CD40 signaling by IL-10 
suppressed multiple sclerosis and rheumatoid arthritis, confirming the value of IL-10 as a 
therapeutic for autoimmunity (Qin et al. 2006). Further, IL-10 was shown to play a role in 
partial suppression of type 1 diabetes (Slavin, Maron, and Weiner 2001; Battaglia et al. 2006; 
Goudy et al. 2001; Goudy et al. 2003). Thus, through activation of several biological 
mechanisms, IL-10 may provide significant enhancement to CTB-diabetes autoantigen 
mediated immune suppression. 
2.7 Virus vaccine delivery does not inhibit immunotolerance 
In addition to its function as a vehicle for subunit vaccine delivery, vaccinia virus was 
shown to stimulate production of anti-inflammatory cytokines IL-10 and TGF-┚ in skin 
epithelial cells(Liu et al. 2005). As these cytokines are known to inhibit inflammation and 
Th1 responses, vaccinia demonstrates properties known to suppress inflammation. Further, 
vaccinia virus expressing the pancreatic islet auto-Ag glutamic acid decarboxylase (GAD) 
was shown to be 90% effective in prevention of diabetes in NOD mice (Jun, Khil, and Yoon 
2002; Jun et al. 2002). (1) Vaccinia multiplies in the cytoplasm, excluding genetic 
modification of infected cells (Moss 1996).  (2) All human cell types tested produce viral 
infection with high efficiency. Viral or foreign proteins are synthesized and undergo 
appropriate post-translational modification (Moss 1991). (3) Multiple autoantigen genes (up 
to 25 kb), can be tolerated in dispensable regions of the vaccinia genome without impacting 
virus growth. (4) Because recombinant vaccinia virus proteins expressed in mammalian cells 
are properly folded, processed and transported normally, they can be used to induce or bind 
antibodies that recognize conformational epitopes (Otteken, Earl, and Moss 1996).  (5) The 
safety of a live attenuated VV vaccine was clearly shown in a major smallpox eradication 
program (Moss 1991). (6) Patients injected with an attenuated VV strain expressing 
cytokines showed no evidence of systemic virus spread, organ dysfunction or other major 
hematological or biochemical changes (Robinson, Cornelius et al. 1998; Robinson, Mukherjee 
et al. 1998; Mastrangelo et al. 1999). (7) Construction of safer, hyper-attenuated replication-
deficient and –competent strains of vaccinia is underway (Denes et al. 2006), which could be 
used for treatment of diabetes.  Recent experiments in our laboratory showed that vaccinia 
virus delivered CTB-INS autoantigens suppress type 1 diabetes insulitis and hyperglycemia 
in NOD mice (Denes, Fodor and Langridge 2010). Of specific relevance to this proposal, 
addition of vaccinia as an alternate CTB-INS delivery vehicle will permit priming and 
boosting CTB-INS immunosuppressive responses without the possibility for generation of 
www.intechopen.com
 
Multi-Component Vaccines for Suppression of Type 1 Diabetes 
 
463 
immunity to the vector, which could potentially ameliorate immunological tolerization to 
the autoantigen and degrade the contribution of the adjuvant to enhanced 
immunosuppression. Further, delivery of subunit vaccines, which are often lacking in 
immunogenicity may benefit from increased immunostimulation provided by heterologous 
prime/boost inoculation regimes. Vaccinia prime, plant boost strategies may provide an 
increased level of immunosuppression.  
2.8 Plants block type 1 diabetes onset and act as production and delivery vehicles for 
diabetes vaccines. 
The B subunit of the AB toxin isolated from the castor oil plant Ricinus communis, when 
linked as a fusion protein at the C-terminus of proinsulin and expressed in potato plants, 
was shown to significantly suppress the onset of type 1 diabetes (Carter et al. 2010; Carter et. 
al. 2006).  Because food plants are generally devoid of pathogen associated molecular 
patterns (PAMPs), they are well tolerated by the inate and adaptive arms of the immune 
system. Their ease of genome manipulation via genetic engineering techniques, their ability 
to correctly modify recombinant proteins while retaining biological activity and their 
simplicity for oral vaccine administration makes them ideal production and delivery 
vehicles for mucosal vaccination (Fuchs and Gonsalves 2007; Horn, Woodard, and Howard 
2004; Streatfield 2006).  Further, the federal government has confirmed the safety of 
transgenic plants for human consumption as no human toxicity has been detected since their 
first appearance two decades ago (Konig et al. 2004; Flachowsky, Chesson, and Aulrich 
2005). Having completed phase 3 trials, several plant synthesized pharmaceuticals have 
already emerged into the marketplace (Horn, Woodard, and Howard 2004). In contrast to 
injected vaccines that stimulate only IgG antibody production, plant based vaccines 
stimulate both IgA and IgG antibody biosynthesis, protecting mucosal epithelia as well as 
blood perfused tissues. Further, plants do not become infected with animal pathogens, and 
since they are delivered by the digestive tract, they eliminate needle based injuries and cross 
infection. In terms of stimulating immunity, heterologous plant prime-boost vaccination 
regimes were shown to generate high levels of antibody protection in mice (Webster et al. 
2006). Important to this review, plant vaccines have also been shown to suppress 
autoimmune diseases (Arakawa, Chong, and Langridge 1998; von Herrath and Whitton 
2000). The addition of immunomodulators to autoantigens in prime-boost regimens was 
shown to significantly enhance immunological suppression of autoimmunity and allergy 
(Ulmer, Wahren, and Liu 2006, 2006).  Alternatively, virus delivered CTB::INS and 
CTB::GAD fusion genes expressed in primate and human cells were shown to partially 
suppress insulitis and hyperglycemia in NOD mice providing the option for development of 
virus prime-plant boost strategies for enhanced suppression of autoimmunity (Denes et al. 
2005; Denes et al. 2006).  Thus, in addition to providing nutrition, transgenic plant tissues 
can provide proteins that both suppress diabetes autoimmunity and serve as production 
and delivery vehicles for multi-component vaccines that can suppress autoimmunity.  
3. Conclusions 
A variety of bacterial and plant enterotoxin B subunit immunomodulatory molecules linked 
to diabetes autoantigens were shown to safely generate substantial increases in 
immunological tolerance in vaccinated prediabetic mice. Additional evidence from NOD 
mouse vaccination experiments showed that this multifactorial vaccination strategy in 
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combination with the anti-inflammatory cytokine IL-10 is both effective and safe for durable 
suppression of chronic insulitis responsible for type 1 diabetes onset. Recent ex vivo 
monocyte derived DC - CTB::autoantigen fusion protein inoculation experiments showed 
that enhancement of immunological tolerance correlated with vaccine suppression of DC 
biosynthesis of co-stimulatory factors CD86, CD83 and CD80. In addition, vaccine 
inoculated DCs were shown to further suppress diabetes autoimmunity by down-regulating 
inflammatory cytokine IL-12 and IL-6 secretion and up-regulating secretion of the anti-
inflammatory cytokine IL-10. In future experiments, incubation of adjuvant-autoantigen 
inoculated DCs with naïve Th0 lymphocytes will determine the degree to which CTB-
autoantigen fusion proteins can stimulate naïve Th0 lymphocyte development into anti-
inflammatory Th2 or regulatory T cells. Further, these experiments may also establish 
whether CTB adjuvant-autoantigen fusion proteins suppress diabetes autoimmunity by 
enhancing DC inhibition of autoreactive Th1 or Th17 lymphocyte development.      
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book provides apt descriptions of cutting edge technologies and applications in the ever going search for
treatments and cure for diabetes. Areas including T cell development, innate immune responses, imaging of
pancreata, potential viral initiators, etc. are considered.
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